Evidence map›Paper›PMID 36930447›Full record

ArticleBrazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]2023

Genomic variations in polymyxin-resistant Pseudomonas aeruginosa clinical isolates and their effects on polymyxin resistance.

Yuan Liang, Jie Li, Yunmin Xu, Yuan He, Bo Jiang, Chunyan Wu, Bin Shan, Hongqiong Shi, Guibo Song

Open access · greenAbstract read
In one paragraph

Article in Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 68% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuan Liang *Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Jie Li *Department of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Yunmin XuDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Yuan HeDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Bo JiangDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Chunyan WuDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Bin ShanDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China.
Hongqiong ShiDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China. 2542757149@qq.com.
Guibo SongDepartment of Clinical Laboratory, First Affiliated Hospital of Kunming Medical University, Kunming, 650032, China. songgb1229@163.com.ORCID http://orcid.org/0000-0002-3934-3583
Kunming Medical University · CNYunnan University · CN

Funding

Special Foundation for National Science and Technology Basic Research Program of China 2019FY101200Special Foundation for National Science and Technology Basic Research Program of China 2019FY101209Yunnan health training project of high level talents H-2018075Yunnan High-level Personnel training support plan YNWR-QNBJ-2020-261
6 · The paper itself

Abstract

Infection with P. aeruginosa, one of the most relevant opportunistic pathogens in hospital-acquired infections, can lead to high mortality due to its low antibiotic susceptibility to limited choices of antibiotics. Polymyxin as last-resort antibiotics is used in the treatment of systemic infections caused by multidrug-resistant P. aeruginosa strains, so studying the emergence of polymyxin-resistant was a must. The present study was designed to define genomic differences between paired polymyxin-susceptible and polymyxin-resistant P. aeruginosa strains and established polymyxin resistance mechanisms, and common chromosomal mutations that may confer polymyxin resistance were characterized. A total of 116 CRPA clinical isolates from patients were collected from three tertiary care hospitals in China during 2017-2021. Our study found that polymyxin B resistance represented 3.45% of the isolated carbapenem-resistant P. aeruginosa (CRPA). No polymyxin-resistant isolates were positive for mcr (1-8 and 10) gene and efflux mechanisms. Key genetic variations identified in polymyxin-resistant isolates involved missense mutations in parR, parS, pmrB, pmrA, and phoP. The waaL and PA5005 substitutions related to LPS synthesis were detected in the highest levels of resistant strain (R1). The missense mutations H398R in ParS (4/4), Y345H in PmrB (4/4), and L71R in PmrA (3/4) were the predominant. Results of the PCR further confirmed that mutation of pmrA, pmrB, and phoP individually or simultaneously did affect the expression level of resistant populations and can directly increase the expression of arnBCADTEF operon to contribute to polymyxin resistance. In addition, we reported 3 novel mutations in PA1945 (2129872_A < G, 2130270_A < C, 2130272_T < G) that may confer polymyxin resistance in P. aeruginosa. Our findings enriched the spectrum of chromosomal mutations, highlighted the complexity at the molecular level, and multifaceted interplay mechanisms underlying polymyxin resistance in P. aeruginosa.

Indexed as

PolymyxinsPseudomonas InfectionsAnti-Bacterial AgentsBacterial ProteinsCarbapenemsDrug Resistance, BacterialGenomicsHumansMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsBacterial ProteinsCarbapenemsPolymyxinsAntimicrobial resistanceLipid ALPS

Identifiers

PMID36930447
PMCPMC10234930
OpenAlexW4327684273

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.